A large upcoming collaborative trial spearheaded by the non-profit Pancreatic Cancer Action Network will take advantage of new insights about pancreatic cancer to test drugs, including combinations, targeted to disease subtypes.
The trial – set to start in Spring 2017 – will include a range of standard-of-care drugs and investigational therapies, hopefully identifying optimal combination approaches along the way. The umbrella trial design will draw on elements of major genomics-driven adaptive trial collaborations that make use of public-private partnerships to test multiple drugs, like I-SPY in breast cancer and Lung-MAP in lung cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?